Vanda Pharmaceuticals (NASDAQ:VNDA) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report sent to investors on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald raised their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an overweight rating in a research report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA remained flat at $5.31 during mid-day trading on Monday. 477,076 shares of the company were exchanged, compared to its average volume of 1,630,284. Vanda Pharmaceuticals has a 12-month low of $3.30 and a 12-month high of $6.75. The company has a 50-day moving average of $5.78 and a two-hundred day moving average of $4.87. The stock has a market capitalization of $309.03 million, a price-to-earnings ratio of -66.38 and a beta of 0.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). The company had revenue of $47.46 million during the quarter, compared to analyst estimates of $48.50 million. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. As a group, research analysts forecast that Vanda Pharmaceuticals will post -0.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Panagora Asset Management Inc. grew its holdings in Vanda Pharmaceuticals by 4.3% in the 2nd quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 2,509 shares during the period. Bank of New York Mellon Corp boosted its holdings in Vanda Pharmaceuticals by 8.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 257,995 shares of the biopharmaceutical company’s stock worth $1,458,000 after acquiring an additional 20,721 shares during the period. SG Americas Securities LLC purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at approximately $61,000. Profit Investment Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 159.3% during the 2nd quarter. Profit Investment Management LLC now owns 571,324 shares of the biopharmaceutical company’s stock valued at $3,228,000 after buying an additional 351,000 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Vanda Pharmaceuticals during the first quarter worth $193,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.